The life of a newly approved drug will extend the lives of cats diagnosed with chronic kidney disease (CKD) by helping them maintain a healthy weight.
The US Food and Drug Administration (FDA) has launched Elura, a proprietary oral capromorelin solution. The product is the first drug specifically approved for the treatment of weight loss in cats with CRF, the agency said.
Capromorelin is a ghrelin receptor agonist that is known to increase appetite and weight gain, according to the FDA. The agency previously approved a solution to stimulate appetite in dogs with the same receptor.
Elura's sponsor Elanco conducted a 56-day field efficacy study comparing the drug to a control group in cats owned by the customer. At the end of the test, the animals given the oral solution had gained weight while those in the control group had lost weight.
Additional safety tests showed that both heart rate and direct blood pressure decreased temporarily and blood sugar levels rose temporarily. Overall, the most common side effects observed were vomiting and hypersalivation, both of which were more common in male cats.
The prescription solution is available in 15 ml bottles with an oral dosing syringe.